Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | KDM1A | O60341 | 2/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27091860 | 0.92 | MEN1 (0.65) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL8696023 | 0.89 | MEN1 (0.60) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL696258 | 0.85 | BCHE (0.68) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL695671 | 0.85 | MEN1 (0.52) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL5539449 | 0.84 | MEN1 (0.65) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL736332 | 0.83 | MEN1 (0.54) | MEN1KMT2APOLBALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL10447064 | 0.83 | MEN1 (0.54) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL15012409 | 0.82 | MEN1 (0.50) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL31650762 | 0.82 | MEN1 (0.50) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL2471248 | 0.81 | KDM1A (0.59) | MEN1KMT2APOLBALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620403-B1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-11-28 | — | — | EP | claimed |
| EP-3509627-A1 | LYSINE SPECIFIC HISTONE DEMETHYLASE-1 INHIBITORS AND USES THEREFOR | University of Canberra (AU) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018045422-A1 | LYSINE SPECIFIC HISTONE DEMETHYLASE-1 INHIBITORS AND USES THEREFOR | UNIVERSITY OF CANBERRA (AU) | 2018-03-15 | — | — | WO | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| WO-2013084241-A1 | COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2013-06-13 | — | — | WO | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| EP-2421828-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF RENIN | Cadila Healthcare Limited (IN) | 2012-02-29 | — | — | EP | disclosed |
| EP-1501830-B1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-7427613-B2 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-23 | — | — | US | disclosed |
| EP-1620403-B1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-11-28 | — | — | EP | disclosed |
| EP-1761509-A2 | SUBSTITUTED CYCLOALKYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-14 | — | — | EP | disclosed |
| US-20060235056-A1 | Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-10-19 | — | — | US | disclosed |
| EP-1620403-A1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005111002-A2 | SUBSTITUTED CYCLOALKYL DERIVATIVES FOR USE IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004096769-A1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | REN, ACE, AGTR1 | MEN1 1386/4885KMT2A 4717/4885POLB 3919/4885 |
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | MEN1 4729/4885KMT2A 1920/4885POLB 4435/4885 |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | MEN1 2389/4885KMT2A 4221/4885POLB 3551/4885 |
| US-20060235056-A1 | Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives | REN, ACE, ACE2 | MEN1 2521/4885KMT2A 3732/4885POLB 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.